Peptide Comparison
Tirzepatide vs Dulaglutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
GLP-1 agonist + insulin or sulfonylureas: High risk per peptide research literature. Hypoglycemia risk: GLP-1 enhances glucose-dependent insulin secretion; stacking with exogenous insulin or secretagogues can drive severe lows.
Data-derived verdict
Tirzepatide and Dulaglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Tirzepatide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tirzepatide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: nausea; diarrhea; pancreatitis risk. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Tirzepatide | Dulaglutide | |
|---|---|---|
| Class | GIP/GLP-1 dual incretin agonist | GLP-1 receptor agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity [1][2] | GLP-1 receptor agonist fused to human IgG4 Fc |
| Route | SC injection | SC injection |
| Half-life | ~5 days | ~5 days |
| Dosage (research) | 2.5 mg SC weekly (Mounjaro/Zepbound label starting dose, escalate by 2.5 mg monthly to label max 15 mg weekly per SURMOUNT escalation schedule) [1][2][3] | 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 262 indexed | 258 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; vomiting; diarrhea; pancreatitis risk; gallbladder disease; thyroid C-cell tumor black-box warning [1][2] | Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tirzepatide or Dulaglutide?
Tirzepatide and Dulaglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Tirzepatide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tirzepatide's evidence base is currently denser.
What is the difference between Tirzepatide and Dulaglutide?
Tirzepatide is classed as GIP/GLP-1 dual incretin agonist; Dulaglutide is classed as GLP-1 receptor agonist. Reported mechanism: Tirzepatide, Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity; Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc. Reported half-life: Tirzepatide, ~5 days; Dulaglutide, ~5 days. Routes in published studies: Tirzepatide, SC injection; Dulaglutide, SC injection.
Which has stronger evidence, Tirzepatide or Dulaglutide?
Tirzepatide and Dulaglutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tirzepatide is graded FDA-Approved, with 73 cited sources on its reference page and 262 indexed studies. Dulaglutide is graded FDA-Approved, with 39 cited sources on its reference page and 258 indexed studies.
Which is more accessible, Tirzepatide or Dulaglutide?
Both Tirzepatide and Dulaglutide are FDA-approved drugs. Catalog status: Tirzepatide, Prescription; Dulaglutide, Prescription.
Are Tirzepatide and Dulaglutide ever combined?
Tirzepatide and Dulaglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…